drugset / Trial / NCT03535350
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Safety of combination of ibrutinib and radiation at various dose levels in unmethylated o6-methylguanine-DNA-methyltransferase (MGMT) glioblastoma and study of ibrutinib, temozolomide, and radiation combination therapy in methylated MGMT glioblastoma.
Timeline
- Start
- 2018-08-24
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 280 mg | — |
| Subject | Ibrutinib | Small molecule | 420 mg | — |
| Subject | Ibrutinib | Small molecule | 560 mg | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |